China-based biotech developer Shanghai Ark Biopharmaceutical Co., Ltd. has received clearance from the U.S. Food and Drug Administration to begin a U.S. clinical study of its experimental anti-fibrotic therapy AK3280 for idiopathic pulmonary fibrosis (IPF).
The agency accepted the company’s investigational new drug application, allowing a Phase 2 proof-of-concept trial to proceed. The planned study will be a multi-center, randomized, partially double-blind trial comparing the oral drug against both placebo and an active control. Researchers will evaluate efficacy, safety and pharmacokinetics in patients diagnosed with IPF, a progressive and often fatal lung disease marked by scarring of lung tissue and declining respiratory function.
IPF remains a serious condition with a median survival of roughly two to five years after diagnosis. Existing therapies — including pirfenidone and nintedanib — can slow disease progression but often cause gastrointestinal side effects such as diarrhea and nausea. These tolerability issues frequently lead to treatment discontinuation, leaving physicians with limited long-term options for disease management.
ArkBio believes its investigational therapy may offer improved tolerability while maintaining clinical effectiveness. The drug is designed as a broad-spectrum small-molecule anti-fibrotic agent targeting pathways involved in tissue scarring. In a prior Phase 2 proof-of-concept study conducted in China, the therapy demonstrated statistically significant improvements in forced vital capacity after 24 weeks, a key measure of lung function in IPF patients. Additional lung performance indicators also improved, suggesting meaningful clinical benefit.
Importantly, the company reported no notable increase in gastrointestinal adverse effects commonly associated with currently approved treatments. Such findings, if confirmed in international trials, could position the therapy as a more patient-friendly option in a disease where adherence is often compromised.
The newly authorized U.S. trial represents a key step in the drug’s global development strategy. Data generated from the study could support future regulatory submissions in the United States and other major markets. The company said it plans to continue advancing the therapy worldwide with the goal of providing patients a more effective and better-tolerated treatment alternative.
Industry observers note that advances in anti-fibrotic therapies are a major focus in pulmonary medicine, as improved tolerability and sustained lung function preservation remain among the most pressing unmet needs for people living with IPF.